X4 Pharmaceuticals, Inc. Common Stock (XFOR) is a publicly traded Healthcare sector company. As of May 21, 2026, XFOR trades at $3.82 with a market cap of $347.10M and a P/E ratio of -19.95. XFOR moved +4.12% today. Year to date, XFOR is -1.82%; over the trailing twelve months it is +39.11%. Its 52-week range spans $1.35 to $26.83. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces XFOR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
X4 Pharmaceuticals Secures EU Approval, Eyes €226m Milestones and Full Phase 3 Enrollment: X4 Pharmaceuticals reported Q1 net loss of $20.2m on $2.7m revenue versus $28.8m a year earlier and held $233.7m cash. The 4WARD Phase 3 chronic neutropenia trial spans over 110 sites with full enrollment due by end-Q3 and EU approval unlocks up to €226m.
| Metric | Value |
|---|---|
| Price | $3.82 |
| Market Cap | $347.10M |
| P/E Ratio | -19.95 |
| EPS | $-0.19 |
| Dividend Yield | 0.00% |
| 52-Week High | $26.83 |
| 52-Week Low | $1.35 |
| Volume | 25 |
| Avg Volume | 0 |
| Revenue (TTM) | $2.56M |
| Net Income | $-37.45M |
| Gross Margin | 68.83% |
1 analysts cover XFOR: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.